Compass Therapeutics, Inc. announced that updated results from the ongoing Phase 2 study of CTX-009 combined with paclitaxel in patients with biliary tract cancer (BTC) will be presented at a poster session of the 2023 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI) taking place in San Francisco, CAJanuary 19-21, 2023. Additional poster presentations by Compass include trials in progress posters for the ongoing Phase 2/3 study of CTX-009 combined with paclitaxel in patients with biliary tract cancers (BTC) and the ongoing Phase 2 study of CTX-009 in patients with metastatic colorectal cancer (CRC).